CAM
JNCE

ClariVest Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

ClariVest Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-710
Closed -$3K – 870
2020
Q1 		$3K Buy
710
+282
+66% +$1.62K ﹤0.01% 620
2019
Q4 		$4K Buy
+428
New +$2.31K ﹤0.01% 562

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

ClariVest Asset Management's JNCE Position: Q2 2020 in Review

ClariVest Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2020, closing a stake of 710 shares — an estimated $3K sold.

ClariVest Asset Management first reported a position in JNCE in Q4 2019 and held it in 2 quarters. The position peaked at $4K in Q4 2019. 90 funds tracked by Wall St. Rank hold JNCE as of Q2 2020.

  • ClariVest Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • ClariVest Asset Management sold 710 Jounce Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $3K.
  • ClariVest Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • ClariVest Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $4K in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2020.

Based on ClariVest Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.